The views expressed in this content represent the perspective and opinions of the author and may or may not represent the position of Indiana University School of Medicine.
Research Communications Manager
Anna Carrera is the research communications manager for Indiana University's Precision Health Initiative, IU School of Medicine and the Indiana Clinical and Translational Sciences Institute. She joined the team in June 2019 after working as a TV news rep...
Two new grants supporting osteosarcoma research have been funded at IU School of Medicine, building on work that has been previously established based on Tyler Trent’s tumor cells. Karen E. Pollok, PhD, is the lead researcher for both of these grants, including $1.9 million from the U.S. Department of Defense and $50,000 from the Sarcoma Foundation of America.
A team of researchers at IU School of Medicine have received $100,000 in pilot funding to research how best to deliver cancer survivorship healthcare to adolescents and young adults in southwest Indiana.
Researchers are learning more about how children’s brain development may be affected when their mother has malaria while she is pregnant, as well as the effect of preventative treatments for malaria during pregnancy on children after birth.
Carmel Egan, PhD, has been named the director for the Office of Clinical Research (OCR). As the new director, Egan will provide leadership and direction for the Office of Clinical Research, which supports the regulatory and compliance oversight for human interventional clinical research whether federally-funded and industry-sponsored interventional human subjects trials.
IU School of Medicine researchers who received federal grants in 2021 were recognized during a special event on Thursday, April 21 at the VanNuys Medical Science Building atrium. This was the first in-person event for IU School of Medicine’s research affairs since the COVID-19 pandemic started more than two years ago.
In 2020, a partnership between Indiana University School of Medicine and Eli Lilly and Company was created to collaborate in specific areas of scientific development. Leaders of this effort say the progress so far from the five year, $5 million collaboration is a good sign for potential expansion in the future.
IU School of Medicine distinguished professor, Debomoy K. Lahiri, PhD, and his team found that “mis”-production of amyloid precursor protein (APP) in the brain contributes to the development of Alzheimer’s disease. Their findings were published in two successive articles in Molecular Psychiatry and Scientific Reports, which are both Nature publications.
Three pediatric researchers, including one from IU School of Medicine, are encouraging parents to get their children vaccinated against COVID-19 as soon as possible. The op-ed about vaccinations which was co-authored by Chandy John, MD, Ryan White Endowed Chair in Pediatric Infectious Diseases at IU School of Medicine, has been published in Inside Sources, as well as being picked up by other media outlets. John said the number of children who are getting sick from COVID-19 should be a wake-up call in itself.
The third IU Grand Challenges webinar about the Precision Health Initiative (PHI) took place in October, focusing on progress in studying and treating multiple myeloma, which is a cancer of the plasma cells in blood. This webinar featured Rafat Abonour, MD, who leads the IU Precision Health Initiative multiple myeloma disease research team, as well as Dorothy Frapwell, a multiple myeloma patient and retired IU general counsel. IU Vice President for Research Fred Cate served as the event’s host.
A new publication with contributions from an IU School of Medicine researcher could change the way doctors treat children diagnosed with Kawasaki disease. James Wood, MD, was the local lead investigator and one of the authors of a paper recently published in The Lancet: Child and Adolescent Health, called “Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.”